Brian Donovan Joins Moximed as Chief Operating Officer

Donovan brings a track record of scaling innovative medical devices

FREMONT, Calif.--(BUSINESS WIRE)--Moximed, an innovative medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced that Brian Donovan has joined the company as Chief Operating Officer.

“Brian has an impressive track record of leading cross-functional teams in the development and scaling of innovative medical devices,” said Chris Gleason, President and CEO of Moximed. “His experience guiding companies from early clinical trials to widespread commercial adoption will be critical to maximize patient impact with the MISHA^® Knee System.”

Prior to joining Moximed, Brian served as Vice President of Research & Development at Boston Scientific. Brian previously held Product Development and Operations leadership roles at multiple medical device companies, including: Relievant Medsystems, Medtronic, and Kyphon.

“I am excited to be joining the Moximed team to help expand the reach of the MISHA Knee System,” said Brian. “Finding an innovative solution to reduce medial compartment loads, while still preserving the knee’s articulating joint surface, is what makes this extra-capsular implantable shock absorber so unique. We are on the path to transforming the lives of millions of people affected by knee OA with this innovative treatment.”

About The MISHA Knee System

Moximed’s MISHA Knee System is for people with medial knee OA who failed to find relief from previous treatments. These patients continue to experience pain that interferes with daily activities, and are ineligible for, or unwilling to undergo, joint replacement due to age or absence of advanced OA.

Knee OA develops when the joint’s natural shock absorbers, cartilage and meniscus, no longer cushion the joint from daily activities, leading to chronic pain and activity limitation. Many people with mild to moderate OA are otherwise healthy, in their prime working years, and have busy lives. For these patients, total knee replacement is a reluctant option, as it is an end-stage treatment for end-stage disease. OA patients without end-stage disease seek options that preserve their knee, activity level, and quality of life.

Reducing weight on painful osteoarthritic joints is known to reduce pain and improve function. The MISHA Knee System is the first implantable shock absorber that reduces weight on the knee joint with every walking step, easing pain, preserving function, and possibly delaying joint replacement surgery. The implant is placed on the medial knee and moves with the natural joint, reducing about 30% of the peak force on the knee with every walking step.

The MISHA Knee System is FDA cleared.

About Moximed

Moximed’s technology, the MISHA Knee System, is the result of over a decade of clinical research and development and is the first implantable shock absorber for the treatment of medial compartment knee osteoarthritis (OA). With experienced med-tech leadership and strong investor support, Moximed is poised to elevate the standard of care and quality of life for millions of pre-arthroplasty knee OA sufferers hindered by arthritic knee pain and function loss. Moximed is based in Fremont, California.

To learn more, visit www.moximed.com.